CALT Calliditas Therapeutics: Accounting Value per Share

Graphic logo of Calliditas Therapeutics AB (CALT)

Calliditas Therapeutics (CALT) revenue relies on a single orphan drug, yet concentration risks are mitigated by its integration into a global medical holding. The book value per share trend reflects the issuer's tangible assets, and this metric has reached the level of 0.37. High margins coupled with low personnel costs are offset by threats from low-cost generics and a potential revision of insurance reimbursement terms.

Calliditas (CALT): Share Book Value from 07/04/2022 to 09/28/2024

Calliditas Therapeutics, Inc. - analytical breakdowns and key metrics (CALT)

- price and consensus price forecast:
Price Chart Calliditas|CALT - Price Target Chart
- market capitalization data:
Market Valuation Calliditas Therapeutics AB|CALT - Aggregate Business Value
- book capitalization data:
Net Assets per Single Share Calliditas Therapeutics|CALT - Net Asset Value|Market Capitalization to Book Value Ratio calliditas.se|CALT - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Calliditas Therapeutics|CALT - Long-Term Debt to Capital|Short-Term Debt to Equity Calliditas|CALT - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Calliditas Therapeutics AB
Fundamental company valuation:calliditas.se - CALT
Manufactured products of Calliditas

Investors are assessing the resilience of Calliditas Therapeutics (CALT) through the net asset value per share after deducting liabilities. By analyzing the book value per share, one can track the transformation of profit into capital, which, for a developer of orphan drugs, confirms a financial foundation secured by patent exclusivity and guaranteed demand for lifelong kidney therapy.

Competitors of Calliditas Therapeutics (CALT)

TVTX - Net Assets per Single Share|Ardelyx Corp (ARDX) - Net Assets per Single Share|PROK - Accounting Value per Share|AKBA (akebia.com) - Book Price of a Share|Net Assets per Single Share Cara Therapeutics TVRD|Share Book Value DiaMedica Therapeutics Inc|Unicycive (UNCY) - Book Value per Share|Accounting Value of a Share Rockwell Medical Inc. (RMTI)|Book Value per Share CVKD (Cadrenal Therapeutics)|conduitpharma.com - Book Value per Share|Net Assets per Single Share Renalytix Plc (RNLX)|ZVSA: Accounting Value of a Share